Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Syneos Health Inc    SYNH

SYNEOS HEALTH INC (SYNH)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Syneos Health Schedules Second Quarter 2018 Earnings Call for Thursday, August 2, 2018

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/13/2018 | 12:03am CEST

RALEIGH, N.C., July 12, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and CCO (Contract Commercial Organization), will release its second quarter 2018 financial results on Thursday, August 2, 2018, prior to its earnings call at 8:00 a.m. ET. 

Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate via telephone, please dial +1 877 930 8058 within the United States or +1 253 336 7551 outside the United States, approximately 15 minutes prior to the scheduled start time. The conference ID for the call is 2556819.

A webcast replay will be available on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com after 1:00 p.m. on August 2. In addition, an audio replay will be available for one week following the call and will be accessible by dialing +1 855 859 2056 within the United States or +1 404 537 3406 outside the United States. The replay ID is 2556819.

About Syneos Health
Syneos Health™ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com.

Investor Relations Contact:                             
Ronnie Speight                                                    
Vice President, Investor Relations                       
+1 919 745 2745                                                  
[email protected]                 

Press/Media Contact:
Danielle DeForge
Executive Director, External Communications
+1 781 425 2624
[email protected]

Primary Logo


© GlobeNewswire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SYNEOS HEALTH INC
07/13Syneos Health Schedules Second Quarter 2018 Earnings Call for Thursday, Augus..
GL
07/04MARKET SURVEY OF CONTRACT RESEARCH O : This market research report on Contract R..
AQ
06/29SYNEOS HEALTH, INC. : Entry into a Material Definitive Agreement, Creation of a ..
AQ
06/29Free Stock Performance Review on Thermo Fisher Scientific and Three Additiona..
AC
06/28CEL SCI : Wins Breach of Contract Ruling against Clinical Research Organization ..
AQ
06/26SYNEOS HEALTH : and Elligo Announce Strategic Collaboration
AQ
06/22Syneos Health to Share Strategies Designed to Meet the Needs of Patients, Pay..
GL
06/22SYNEOS HEALTH : and Elligo Announce Strategic Collaboration to Advance Clinical ..
AQ
06/21Syneos Health and Elligo Announce Strategic Collaboration to Advance Clinical..
GL
06/13SYNEOS HEALTH : to lay off 98 amid changing business needs
AQ
More news
News from SeekingAlpha
06/13Syneos Health (SYNH) Presents At William Blair 2018 Growth Stock Conference -.. 
05/09Syneos Health, Inc. 2018 Q1 - Results - Earnings Call Slides 
05/09Syneos Health's (SYNH) CEO Alistair Macdonald on Q1 2018 Results - Earnings C.. 
05/09Syneos Health beats by $0.04, beats on revenue 
05/08Notable earnings before Wednesday?s open 
Financials ($)
Sales 2018 4 461 M
EBIT 2018 448 M
Net income 2018 26,0 M
Debt 2018 2 509 M
Yield 2018 -
P/E ratio 2018 203,16
P/E ratio 2019 35,60
EV / Sales 2018 1,67x
EV / Sales 2019 1,51x
Capitalization 4 959 M
Chart SYNEOS HEALTH INC
Duration : Period :
Syneos Health Inc Technical Analysis Chart | SYNH | US87166B1026 | 4-Traders
Technical analysis trends SYNEOS HEALTH INC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 51,9 $
Spread / Average Target 3,4%
EPS Revisions
Managers
NameTitle
Alistair Macdonald Chief Executive Officer & Director
Michael A. Bell Chairman
Jason M. Meggs Chief Financial Officer & Executive Vice President
Kenneth F. Meyers Independent Director
Linda S. Harty Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SYNEOS HEALTH INC15.14%4 959
CELLTRION, INC.--.--%32 245
IQVIA HOLDINGS INC13.49%22 746
LONZA GROUP8.17%21 355
INCYTE CORPORATION-25.97%14 861
SEATTLE GENETICS, INC.31.33%11 158